Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers.

Bhatt DL, Pollack CV, Weitz JI, Jennings LK, Xu S, Arnold SE, Umstead BR, Mays MC, Lee JS.

N Engl J Med. 2019 Mar 17. doi: 10.1056/NEJMoa1901778. [Epub ahead of print]

PMID:
30883047
2.

Hyperemesis Gravidarum.

Jennings LK, Krywko DM.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Jan 16.

3.

Entropically driven aggregation of bacteria by host polymers promotes antibiotic tolerance in Pseudomonas aeruginosa.

Secor PR, Michaels LA, Ratjen A, Jennings LK, Singh PK.

Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10780-10785. doi: 10.1073/pnas.1806005115. Epub 2018 Oct 1.

PMID:
30275316
4.

Yeast-based screening of natural product extracts results in the identification of prion inhibitors from a marine sponge.

Jennings LK, Ahmed I, Munn AL, Carroll AR.

Prion. 2018;12(3-4):234-244. doi: 10.1080/19336896.2018.1513315. Epub 2018 Sep 13.

PMID:
30165789
5.

Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial.

Tricoci P, Neely M, Whitley MJ, Edelstein LC, Simon LM, Shaw C, Fortina P, Moliterno DJ, Armstrong PW, Aylward P, White H, Van de Werf F, Jennings LK, Wallentin L, Held C, Harrington RA, Mahaffey KW, Bray PF.

Blood Cells Mol Dis. 2018 Sep;72:37-43. doi: 10.1016/j.bcmd.2018.07.004. Epub 2018 Jul 21.

6.

Pelvic Inflammatory Disease (PID).

Jennings LK, Krywko DM.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Feb 11.

7.

Massive Transfusion.

Jennings LK, Watson S.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 Feb 28.

8.

Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction.

Borst O, Münzer P, Alnaggar N, Geue S, Tegtmeyer R, Rath D, Droppa M, Seizer P, Heitmeier S, Heemskerk JWM, Jennings LK, Storey RF, Angiolillo DJ, Rocca B, Spronk H, Ten Cate H, Gawaz M, Geisler T.

Blood Adv. 2018 Mar 27;2(6):715-730. doi: 10.1182/bloodadvances.2017013573.

9.

Filamentous Bacteriophage Produced by Pseudomonas aeruginosa Alters the Inflammatory Response and Promotes Noninvasive Infection In Vivo.

Secor PR, Michaels LA, Smigiel KS, Rohani MG, Jennings LK, Hisert KB, Arrigoni A, Braun KR, Birkland TP, Lai Y, Hallstrand TS, Bollyky PL, Singh PK, Parks WC.

Infect Immun. 2016 Dec 29;85(1). pii: e00648-16. doi: 10.1128/IAI.00648-16. Print 2017 Jan.

10.

Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent Pseudomonas aeruginosa biofilms.

Baker P, Hill PJ, Snarr BD, Alnabelseya N, Pestrak MJ, Lee MJ, Jennings LK, Tam J, Melnyk RA, Parsek MR, Sheppard DC, Wozniak DJ, Howell PL.

Sci Adv. 2016 May 20;2(5):e1501632. doi: 10.1126/sciadv.1501632. eCollection 2016 May.

11.

A prospective study of platelet function in trauma patients.

Ramsey MT, Fabian TC, Shahan CP, Sharpe JP, Mabry SE, Weinberg JA, Croce MA, Jennings LK.

J Trauma Acute Care Surg. 2016 May;80(5):726-32; discussion 732-3. doi: 10.1097/TA.0000000000001017.

PMID:
26895088
12.

The utility of tetraspanin CD9 as a biomarker for metastatic clear cell renal cell carcinoma.

Garner JM, Herr MJ, Hodges KB, Jennings LK.

Biochem Biophys Res Commun. 2016 Feb 26;471(1):21-5. doi: 10.1016/j.bbrc.2016.02.008. Epub 2016 Feb 12.

PMID:
26855131
13.

Biofilm assembly becomes crystal clear - filamentous bacteriophage organize the Pseudomonas aeruginosa biofilm matrix into a liquid crystal.

Secor PR, Jennings LK, Michaels LA, Sweere JM, Singh PK, Parks WC, Bollyky PL.

Microb Cell. 2015 Dec 31;3(1):49-52. doi: 10.15698/mic2016.01.475.

14.

Platelet function recovery following exposure to triple anti-platelet inhibitors using an in vitro transfusion model.

Bhal V, Herr MJ, Dixon M, Akins S, Hord E, White MM, Seiffert D, Kotha J, Jennings LK.

Thromb Res. 2015 Dec;136(6):1216-23. doi: 10.1016/j.thromres.2015.09.009. Epub 2015 Sep 11.

PMID:
26412559
15.

Polydopamine Integrated Nanomaterials and Their Biomedical Applications.

Chen X, Huang Y, Yang G, Li J, Wang T, Schulz OH, Jennings LK.

Curr Pharm Des. 2015;21(29):4262-75. Review.

PMID:
26323424
16.

Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the Pseudomonas aeruginosa biofilm matrix.

Jennings LK, Storek KM, Ledvina HE, Coulon C, Marmont LS, Sadovskaya I, Secor PR, Tseng BS, Scian M, Filloux A, Wozniak DJ, Howell PL, Parsek MR.

Proc Natl Acad Sci U S A. 2015 Sep 8;112(36):11353-8. doi: 10.1073/pnas.1503058112. Epub 2015 Aug 26.

17.

The spectrum of thrombin in acute coronary syndromes.

Giri S, Jennings LK.

Thromb Res. 2015 May;135(5):782-7. doi: 10.1016/j.thromres.2015.02.013. Epub 2015 Feb 21. Review.

PMID:
25764910
18.

Self-compassion and life satisfaction in gay men.

Jennings LK, Philip Tan P.

Psychol Rep. 2014 Dec;115(3):888-95. doi: 10.2466/21.07.PR0.115c33z3.

PMID:
25539176
19.

Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.

Tricoci P, Lokhnygina Y, Huang Z, Van de Werf F, Cornel JH, Chen E, Wallentin L, Held C, Aylward PE, Moliterno DJ, Jennings LK, White HD, Armstrong PW, Harrington RA, Strony J, Mahaffey KW.

Am Heart J. 2014 Dec;168(6):869-77.e1. doi: 10.1016/j.ahj.2014.09.002. Epub 2014 Sep 16.

PMID:
25458650
20.

Tetraspanin CD9 regulates cell contraction and actin arrangement via RhoA in human vascular smooth muscle cells.

Herr MJ, Mabry SE, Jennings LK.

PLoS One. 2014 Sep 3;9(9):e106999. doi: 10.1371/journal.pone.0106999. eCollection 2014.

21.

Benzimidazole analogs as potent hypoxia inducible factor inhibitors: synthesis, biological evaluation, and profiling drug-like properties.

Chen J, Wang J, Schwab LP, Park KT, Seagroves TN, Jennings LK, Miller DD, Li W.

Anticancer Res. 2014 Aug;34(8):3891-904.

22.

PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.

Judge HM, Jennings LK, Moliterno DJ, Hord E, Ecob R, Tricoci P, Rorick T, Kotha J, Storey RF.

Platelets. 2015;26(3):236-42. doi: 10.3109/09537104.2014.902924. Epub 2014 Apr 21.

PMID:
24750101
23.

Tetraspanin CD9 modulates human lymphoma cellular proliferation via histone deacetylase activity.

Herr MJ, Longhurst CM, Baker B, Homayouni R, Speich HE, Kotha J, Jennings LK.

Biochem Biophys Res Commun. 2014 May 16;447(4):616-20. doi: 10.1016/j.bbrc.2014.04.046. Epub 2014 Apr 18.

PMID:
24747564
24.

ChIP-Seq and RNA-Seq reveal an AmrZ-mediated mechanism for cyclic di-GMP synthesis and biofilm development by Pseudomonas aeruginosa.

Jones CJ, Newsom D, Kelly B, Irie Y, Jennings LK, Xu B, Limoli DH, Harrison JJ, Parsek MR, White P, Wozniak DJ.

PLoS Pathog. 2014 Mar 6;10(3):e1003984. doi: 10.1371/journal.ppat.1003984. eCollection 2014 Mar.

25.

The Utility of Platelet and Coagulation Testing of Antithrombotics: Fusing Science with Patient Care.

Jennings LK, Kotha J.

Drug Dev Res. 2013 Dec;74(8):587-593. Epub 2013 Nov 15.

26.

Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.

Speich HE, Bhal V, Houser KH, Caughran AT, Lands LT, Houng AK, Bäckstrom J, Enerbäck M, Reed GL, Jennings LK.

J Cardiovasc Pharmacol. 2014 Jun;63(6):520-7. doi: 10.1097/FJC.0000000000000076.

PMID:
24477045
27.

Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).

Mahaffey KW, Huang Z, Wallentin L, Storey RF, Jennings LK, Tricoci P, White HD, Armstrong PW, Aylward PE, Moliterno DJ, Van de Werf F, Chen E, Leonardi S, Rorick T, Held C, Strony J, Harrington RA.

Am J Cardiol. 2014 Mar 15;113(6):936-44. doi: 10.1016/j.amjcard.2013.11.052. Epub 2013 Dec 25.

PMID:
24444781
28.

Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.

Storey RF, Kotha J, Smyth SS, Moliterno DJ, Rorick TL, Moccetti T, Valgimigli M, Dery JP, Cornel JH, Thomas GS, Huber K, Harrington RA, Hord E, Judge HM, Chen E, Strony J, Mahaffey KW, Tricoci P, Becker RC, Jennings LK.

Thromb Haemost. 2014 May 5;111(5):883-91. doi: 10.1160/TH13-07-0624. Epub 2014 Jan 9.

PMID:
24402559
29.

Pro-MMP-9 upregulation in HT1080 cells expressing CD9 is regulated by epidermal growth factor receptor.

Herr MJ, Mabry SE, Jameson JF, Jennings LK.

Biochem Biophys Res Commun. 2013 Dec 6;442(1-2):99-104. doi: 10.1016/j.bbrc.2013.11.021. Epub 2013 Nov 16.

30.

Tetraspanin CD9 promotes the invasive phenotype of human fibrosarcoma cells via upregulation of matrix metalloproteinase-9.

Herr MJ, Kotha J, Hagedorn N, Smith B, Jennings LK.

PLoS One. 2013 Jun 28;8(6):e67766. doi: 10.1371/journal.pone.0067766. Print 2013.

31.

Hexavalent chromium reduction by Cellulomonas sp. strain ES6: the influence of carbon source, iron minerals, and electron shuttling compounds.

Field EK, Gerlach R, Viamajala S, Jennings LK, Peyton BM, Apel WA.

Biodegradation. 2013 Jun;24(3):437-50. doi: 10.1007/s10532-012-9600-7. Epub 2012 Nov 8.

PMID:
23135488
32.

Elevating local concentrations of GPIIb-IIIa antagonists counteracts platelet thrombus stability.

Speich HE, Furman RR, Lands LT, Moodie GD, Jennings LK.

J Thromb Thrombolysis. 2013 Jul;36(1):31-41. doi: 10.1007/s11239-012-0814-7.

33.

Initiation of rivaroxaban following low molecular weight heparin for thromboprophylaxis after total joint replacement: the Safe, Simple Transitions (SST) study.

Mills RM, Berkowitz RD, Damaraju CV, Jennings LK, Wildgoose P.

Thromb Res. 2012 Nov;130(5):709-15. doi: 10.1016/j.thromres.2012.07.014. Epub 2012 Aug 2.

PMID:
22857800
34.

Phevalin (aureusimine B) production by Staphylococcus aureus biofilm and impacts on human keratinocyte gene expression.

Secor PR, Jennings LK, James GA, Kirker KR, Pulcini ED, McInnerney K, Gerlach R, Livinghouse T, Hilmer JK, Bothner B, Fleckman P, Olerud JE, Stewart PS.

PLoS One. 2012;7(7):e40973. doi: 10.1371/journal.pone.0040973. Epub 2012 Jul 13. Erratum in: PLoS One. 2012;7(10). doi:10.1371/annotation/0fc3d60c-8ae4-4f04-be17-d5d245b4eef5.

35.

Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial.

Angiolillo DJ, Welsh RC, Trenk D, Neumann FJ, Conley PB, McClure MW, Stephens G, Kochman J, Jennings LK, Gurbel PA, Wójcik J, Dabrowski M, Saucedo JF, Stumpf J, Buerke M, Broderick S, Harrington RA, Rao SV.

Circ Cardiovasc Interv. 2012 Jun;5(3):347-56. doi: 10.1161/CIRCINTERVENTIONS.111.965608. Epub 2012 May 22.

PMID:
22619259
36.

Hematoma-inspired alginate/platelet releasate/CaPO4 composite: initiation of the inflammatory-mediated response associated with fracture repair in vitro and ex vivo injection delivery.

McCanless JD, Jennings LK, Bumgardner JD, Cole JA, Haggard WO.

J Mater Sci Mater Med. 2012 Aug;23(8):1971-81. doi: 10.1007/s10856-012-4672-9. Epub 2012 May 16.

PMID:
22588505
37.

Cardiovascular devices and platelet interactions: understanding the role of injury, flow, and cellular responses.

Rowley JW, Finn AV, French PA, Jennings LK, Bluestein D, Gross PL, Freedman JE, Steinhubl SR, Zimmerman GA, Becker RC, Dauerman HL, Smyth SS; 2011 Platelet Colloquium Participants.

Circ Cardiovasc Interv. 2012 Apr;5(2):296-304. doi: 10.1161/CIRCINTERVENTIONS.111.965426. Review. No abstract available.

38.

Induction of the early inflammatory-mediated cellular responses of fracture healing in vitro using platelet releasate-containing alginate/CaPO4 biomaterials for early osteoarthritis prevention.

McCanless JD, Jennings LK, Cole JA, Bumgardner JD, Haggard WO.

J Biomed Mater Res A. 2012 May;100(5):1107-14. doi: 10.1002/jbm.a.34038. Epub 2012 Feb 15.

PMID:
22337563
39.

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.

Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL.

Eur J Clin Pharmacol. 2012 Jul;68(7):1049-56. doi: 10.1007/s00228-012-1217-6. Epub 2012 Feb 8.

PMID:
22315147
40.

Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response.

Jennings LK, Michelson AD, Jacoski MV, Tyagi A, Grgurevich S, Li JS, Picolo Investigators.

Platelets. 2012;23(6):430-8. doi: 10.3109/09537104.2011.650244. Epub 2012 Feb 6.

PMID:
22309046
41.

In vitro differentiation and biocompatibility of mesenchymal stem cells on a novel platelet releasate-containing injectable composite.

McCanless JD, Jennings LK, Cole JA, Bumgardner JD, Haggard WO.

J Biomed Mater Res A. 2012 Jan;100(1):220-9. doi: 10.1002/jbm.a.33256. Epub 2011 Oct 31.

PMID:
22042623
42.

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.

Kosoglou T, Reyderman L, Kasserra C, Jennings LK, Young S, Xuan F, Pei J, Maxwell SE, Schiller J, Meehan AG, Cutler DL.

Eur J Clin Pharmacol. 2012 Mar;68(3):291-300. doi: 10.1007/s00228-011-1127-z. Epub 2011 Oct 4.

PMID:
21969227
43.

Tetraspanins and tumor progression.

Richardson MM, Jennings LK, Zhang XA.

Clin Exp Metastasis. 2011 Mar;28(3):261-70. doi: 10.1007/s10585-010-9365-5. Epub 2010 Dec 24. Review.

PMID:
21184145
44.

Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease.

Pasquali SK, Yow E, Jennings LK, Li JS.

Congenit Heart Dis. 2010 Nov-Dec;5(6):552-5. doi: 10.1111/j.1747-0803.2010.00461.x.

45.

Assessment of eptifibatide clearance by hemodialysis using an in vitro system.

Hudson JQ, McNeely EB, Green CA, Jennings LK.

Blood Purif. 2010;30(4):266-71. doi: 10.1159/000320766. Epub 2010 Nov 11.

PMID:
21071937
46.

Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions.

Becker RC, Gibson CM, Jennings LK, Morrow DA.

Am J Cardiol. 2010 Oct 15;106(8):S2-3. doi: 10.1016/j.amjcard.2010.08.026.

PMID:
20920638
47.

CD9 Expression by Human Granulosa Cells and Platelets as a Predictor of Fertilization Success during IVF.

Jaslow CR, Patterson KS, Cholera S, Jennings LK, Ke RW, Kutteh WH.

Obstet Gynecol Int. 2010;2010. pii: 192461. doi: 10.1155/2010/192461. Epub 2010 Sep 1.

48.

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA; Working Group on High On-Treatment Platelet Reactivity.

J Am Coll Cardiol. 2010 Sep 14;56(12):919-33. doi: 10.1016/j.jacc.2010.04.047.

49.
50.

Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.

Jennings LK.

Thromb Haemost. 2009 Aug;102(2):248-57. doi: 10.1160/TH09-03-0192. Review.

PMID:
19652875

Supplemental Content

Loading ...
Support Center